Related Experiment Video
Updated: Mar 3, 2026
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in
Hyo Joo Byun1, Pramod Darvin1, Dong Young Kang1
1Department of Pathology, School of Medicine, Institute of Biomedical Science and Technology, Konkuk University, Chungju 27478, Republic of Korea.
Abstract:
Worldwide, breast cancer (BCa) is the most common cancer in women. Among its subtypes, triple-negative breast cancer (TNBC) is an aggressive form associated with diminished survival. TNBCs are characterized by their absence, or minimal expression, of the estrogen and progesterone receptors, as well as the human epidermal growth factor receptor 2 (i.e. ER-/-, PR-/-, Her2-/Low). Consequently, treatment for this subtype of BCa remains problematic. Silibinin, a derivative of the flavonoid silymarin, is reported to have anticancer activities against hepatic and non-small cell lung cancers. We hypothesized that silibinin might inhibit cell-extracellular matrix interactions via the regulation, expression, and activation of STAT3 in TNBCs, which could directly inhibit metastasis in silibinin-treated BCa cells. Using proliferation assays, we found that exposure to silibinin at a concentration of 200 µM inhibited the proliferation of breast cancer (BCa) cells; this concentration also inhibited phosphorylation of STAT3 and its principal upstream kinase, Jak2. Furthermore, we found that silibinin inhibited the nuclear translocation of STAT3, as well as its binding to the MMP2 gene promoter. The ability of silibinin to inhibit metastasis was further studied using an in vitro invasion assay. The results confirm the role of STAT3 as a critical mediator in the invasive potential of BCa cells, and STAT3 knock-down resulted in inhibition of invasion. The invasion ability of silibinin-treated BCa cells was studied in detail with the expression of MMP2. Prevention of STAT3 activation also resulted in the inhibition of MMP2 expression. Use of a small interfering RNA to knock down STAT3 (siSTAT3) allowed us to confirm the role of STAT3 in regulating MMP2 expression, as well as the mechanism of action of silibinin in inhibiting MMP2. Taken together, we found that silibinin inhibits the Jak2/STAT3/MMP2 signaling pathway, and inhibits the proliferation, migration, and invasion of triple-negative BCa cells.
Insights
Silibinin effectively inhibits triple-negative breast cancer (TNBC) proliferation and metastasis by blocking the Jak2/STAT3/MMP2 pathway. This flavonoid derivative shows promise in targeting aggressive breast cancer subtypes.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
- Silibinin, a flavonoid derivative, exhibits anticancer properties in various cancer types.
- The STAT3 signaling pathway plays a crucial role in cancer cell proliferation and metastasis.
Purpose of the Study:
- To investigate the potential of silibinin in inhibiting cell-extracellular matrix interactions in TNBC.
- To elucidate the role of STAT3 regulation in silibinin's anti-metastatic effects.
- To determine if silibinin affects the Jak2/STAT3/MMP2 signaling pathway in TNBC cells.
Main Methods:
- Breast cancer cell proliferation assays were performed.
- Western blotting was used to assess protein phosphorylation and expression (STAT3, Jak2, MMP2).
- Nuclear translocation and gene promoter binding assays were conducted for STAT3.
- In vitro invasion assays and STAT3 knockdown (siSTAT3) were utilized to evaluate metastatic potential.
Main Results:
- Silibinin (200 µM) inhibited TNBC cell proliferation and phosphorylation of STAT3 and Jak2.
- Silibinin suppressed STAT3 nuclear translocation and binding to the MMP2 promoter.
- STAT3 knockdown inhibited TNBC cell invasion, confirming its role in metastasis.
- Silibinin treatment reduced MMP2 expression, and STAT3 inhibition prevented this reduction.
Conclusions:
- Silibinin effectively inhibits proliferation, migration, and invasion of triple-negative breast cancer cells.
- The mechanism involves the inhibition of the Jak2/STAT3/MMP2 signaling pathway.
- Silibinin represents a potential therapeutic agent for aggressive breast cancer subtypes.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
02:23Abnormal Proliferation
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...